(Meditation on A Midwestern Doctor’s “What Everyone Needs to Know About Antidepressants”)

There is a particular kind of modern cruelty that dresses itself up as kindness. It speaks in soothing tones, and it often believes its own press releases. If you show it a person who is suffering, it will not ask first what has gone wrong in his life, or what has been done to him, or what he has tried already. It will ask a narrower question: What can we prescribe that looks like action?

That is the mood in which antidepressants became ordinary: not “a tool for severe cases, used with caution,” but an ambient cultural background. Something you drift on to and stay on, and then struggle to drift off again.

A Midwestern Doctor’s long article on SSRIs is angry about this, sometimes too angry. He describes SSRI antidepressants as “one of the most harmful medications on the market” and argues that, because they are so widely prescribed, they have “had a profound effect on the consciousness of our entire society.” Whether or not you like his political flavour, he is pointing at something real: these drugs do not merely alter symptoms, they alter people.

Even if you support antidepressants in principle, you should be unsettled by how casually they are handed out. You should be unsettled by how little informed consent many patients give. You should be unsettled by how hard it can be to stop.

But you should also be unsettled by another failure, which is common in anti-psychiatry writing: the failure to admit that some people really do need an emergency exit. In certain cases, SSRIs are not good, but they are the least bad option available. A drowning man does not demand a perfect rope.

So I will take a position that is unfashionable in both camps. Antidepressants are often a bad bargain. They are often over-prescribed. Withdrawal is under-discussed. Sexual harms are minimised. Emotional flattening is brushed off as “stability”. Yet there remain cases in which a person is so trapped and so functionally destroyed, that medication is a lesser evil while other supports are built.

The adult task is to hold both truths at once.

The most persuasive sections of the Midwestern Doctor’s piece are not the grand claims about civilisation, but the simple ones about clinical reality. He notes that many patients are not warned about side effects such as emotional numbing and sexual dysfunction. In his words, prescribers often fail to warn patients about “becoming numb to life” or “losing the ability to have sex.” That matters because these are not trivial inconveniences. They are life-shaping harms, particularly for young people.

This is not merely anecdotal. European regulators have explicitly acknowledged that sexual dysfunction can be long-lasting even after stopping SSRIs/SNRIs, and they recommended product information wording to reflect reports of symptoms continuing “despite discontinuation.” (European Medicines Agency (EMA))

It is difficult to overstate how important that is. It means that, at minimum, the possibility of persistence is serious enough for regulators to treat it as a labelling issue. That does not tell you the incidence. It does not prove permanence in every case. It does tell you that the old, breezy reassurance—stop the drug and everything returns to normal—is not good enough.

The Midwestern Doctor also describes what many patients recognise as a kind of cultural gaslighting: if you develop agitation, insomnia, derealisation, emotional blunting, or sexual dysfunction on a drug, the system is tempted to interpret those effects as “your illness” rather than the medication. He calls this “widespread denial in psychiatry about the issues with their drugs,” and he points to the familiar escalation cycle: the adverse reaction is treated as diagnostic evidence that you need more medication.

This is plausible because the symptoms overlap. Agitation can look like anxiety. Flattening can look like depression. Withdrawal can look like relapse. A busy clinician, following a simple narrative, can get it wrong. The patient pays the price.

A major point of the essay is that SSRIs can be difficult to stop. He writes that “patients frequently get severely ill when they attempt to stop them” and that “very few doctors know how to safely facilitate this.”

On this, even official UK guidance is now far more explicit than it used to be. NICE’s CKS states that antidepressant withdrawal “may take weeks, months (or longer).” (CKS) The Royal College of Psychiatrists likewise acknowledges that withdrawal can, for some, last “months or more than a year,” and that it is not currently possible to predict who will be hit hardest. (www.rcpsych.ac.uk)

Those statements alone should change how antidepressants are prescribed. If a medication can be difficult to stop, the decision to start it deserves more humility.

There is still a live scientific argument about incidence and severity. Some recent reviews report lower withdrawal rates than older estimates, and they point out that many studies include short-term users who are less likely to suffer severe withdrawal. (The Guardian) The Midwestern Doctor prefers the higher-end estimates. He cites a “recent meta-analysis” claiming “56%… experience withdrawals” and that “46%… experience severe withdrawals.” Those figures appear in some summaries and surveys, but they are debated. This is exactly why the conversation needs to be careful. Overstating the rate invites dismissal. Understating the risk leaves real people abandoned.

The practical conclusion does not depend on the exact number. Withdrawal exists, sometimes it is brutal, and systems that treat it as “rare” or “psychological” are failing.

The Midwestern Doctor is at his most incendiary when he discusses violence. He claims SSRIs can trigger “psychotic violence,” and he describes extreme cases of suicide, homicide, akathisia, and dissociative experiences. He also argues that regulators and companies covered up known risks.

Here, the truth is uncomfortable and more limited than his rhetoric suggests. Regulators have long warned about increased suicidal thinking and behaviour in children, adolescents, and young adults during the early period of antidepressant treatment. The FDA states that analyses showed a “greater risk of suicidality during the first few months of treatment,” with an average risk of such events on drug of about 4% versus 2% on placebo in the trials they analysed. (U.S. Food and Drug Administration)

That is not a minor footnote. It means that starting an SSRI, especially in younger patients, requires monitoring and a willingness to stop or change course if agitation or suicidal ideation emerges.

Where the Midwestern Doctor goes too far is in implying a single explanatory narrative for public violence. Rare catastrophic events are multi-causal and confounded. Even if SSRIs raise risk in a vulnerable subgroup, it does not follow that they are the hidden motor of modern social collapse. That kind of move is emotionally satisfying, but intellectually lazy.

The sober position is still disturbing enough: SSRIs can, in some people, be activating rather than calming, and that activation can interact dangerously with risk of suicide or other forms of self-harm, with impulsivity, and with akathisia. That warrants caution without requiring a grand conspiracy frame.

A Midwestern Doctor spends a lot of time on the political economy of pharmaceuticals. Sometimes he overstates, but he is pointing at a structural truth: in medicine, what gets studied and what gets funded is not just a matter of scientific curiosity. It is also a matter of incentives.

Here is how the machine can deform reality without anyone needing to behave like a cartoon villain.

First, depression is a commercially convenient diagnosis. It is partly subjective. It relies on symptom scales. It is influenced by social conditions. That does not mean it is fake. It means it is easier to turn into a mass market. When endpoints are fuzzy, results are easier to spin, and marginal effects can be framed as dramatic wins.

Second, regulators tend to privilege what can be standardised, trialled, and patented. Large-scale trials require money. Patented products have money behind them. Low-cost, labour-intensive interventions—therapy access, tapering clinics, lifestyle supports, long-term follow-up—often do not. The result is a research pipeline that naturally leans towards drugs and away from non-drug solutions.

Third, overworked clinicians treat guidelines as lifeboats. In an ideal world, every SSRI prescription would be a structured project: clear diagnosis, discussion of risks, planned review, and an exit strategy. In the real world, many prescriptions are written in ten minutes, with vague follow-up. That is not always malice. It is often triage.

This is why the Midwestern Doctor’s bitterness resonates. It is not that every prescriber is corrupt. It is that the system repeatedly channels people towards the same simplified solution, even when it is not appropriate.

The Midwestern Doctor briefly admits an important nuance:

“While many patients react badly to SSRIs, there is also a subset of patients… who benefit greatly from them.”

That is the crack in the door where reality enters. I will open it wider. There are people for whom antidepressants are a lesser evil:

• A person with severe major depression who cannot eat, cannot sleep, and cannot function.
• A person with high suicidal risk where immediate symptom relief is needed while therapy, family support, and practical safeguards are mobilised.
• A person with disabling OCD whose life is being consumed by compulsions and intrusive thoughts.

In those cases, the moral posture of refusing medication “on principle” can become a form of negligence. A tool that is dangerous can still be the right tool in a particular emergency.

But that does not justify the way antidepressants are currently treated as cultural wallpaper.

A sensible ethics of prescribing would include at least four rules:

1. Informed consent must include sexual dysfunction, emotional blunting, and withdrawal risk, not as rare curiosities but as meaningful possibilities. European regulators have explicitly acknowledged long-lasting sexual dysfunction reports. (European Medicines Agency (EMA))
2. Early treatment requires monitoring, especially in the under-25s, because suicidality risk can increase early on. (U.S. Food and Drug Administration)
3. Dose changes should be treated as biologically significant events. Patients often report destabilisation after changes. That does not prove causality in every case. It is enough to justify caution.
4. Every prescription should include an exit plan, even if the plan is “review in X weeks and decide”. NICE recognises that withdrawal can take months or longer. (CKS)

These are not radical demands. They are the minimum that a grown-up system would provide.

The Midwestern Doctor argues SSRIs have changed “the consciousness of our entire society.” That sounds grandiose until you look around and notice how many people report feeling flattened, dulled, less sexual, less alive, less able to cry, less able to rage, and oddly detached from meaning.

Even if you believe antidepressants help some people, it is not healthy for a society to treat chemical emotional management as the default response to misery. Negative emotion is not always pathology. Sometimes it is information. Sometimes it is a signal that something in your life is wrong. Turning off the signal can, in certain situations, prevent you from leaving the conditions that are harming you.

That is one of the most quietly tragic possibilities: the drug that helps you cope also helps you tolerate what you should not tolerate.

Which brings us back to the central question: are we using antidepressants to rescue people, or to help them endure a life that our institutions have made increasingly unliveable?

A Midwestern Doctor’s article is not perfectly balanced, and it sometimes cannot resist turning every issue into a morality tale about elites, agencies, and cover-ups. Still, it is doing something valuable. It is trying to restore moral seriousness to a decision that has become casual.

In a sane culture, antidepressants would be treated like powerful instruments with sharp edges. In ours, they are often treated like a lifestyle product.

That is why the argument will not go away.

Suggested WordPress title and SEO metadata

Title: Antidepressants and the Soft Tyranny of “Help”: A Reluctant Case for Cautious Use
Description: A sceptical but fair-minded look at SSRIs: common harms, withdrawal realities, sexual side effects, and the limited cases where they may still be the lesser evil.
Keywords: SSRIs, antidepressants, withdrawal, emotional blunting, PSSD, informed consent, NICE guidance, suicidality warning

If you would like, I can also produce a second version that is more explicitly “Sebastian at school” (more youthful, slightly more personal framing), while keeping the same factual backbone and the same quoted lines.